Higher levels of CD19(+) leukocytes in Gaucher disease patients as a potential marker for malignancy

Basit Öğe Kaydı
dc.contributor.authorDondurmaci, Meral
dc.contributor.authorCanda, Ebru
dc.contributor.authorKose, Melis
dc.contributor.authorUcar, Sema Kalkan
dc.contributor.authorCoker, Mahmut
dc.contributor.authorSagin, Ferhan
dc.contributor.authorSozmen, Eser Y.
dc.date.accessioned2019-10-27T10:46:27Z
dc.date.available2019-10-27T10:46:27Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractAim: Gaucher disease is an autosomal recessive lysosomal storage disease caused by insufficient glucocerebrosidase activity resulting in accumulation of glucosylceramide, particularly in macrophages. Multiple myeloma and B cell lymphoma are considered to be one of the causes of death from GD in the long term. We aimed to compare cell surface antigens of leukocytes to try to identify a reliable marker for leukocyte infiltration and progression to lymphoid malignancy. Material ve Method: 10 Gaucher disease patients and 20 age-matched healthy controls were included. Leukocytes were collected from whole blood using a Ficoll gradient, stained for specific cell surface antigens (CD33, CD19, CD14, and CD8) and sorted by flow cytometry. Levels of each leukocyte cell surface antigen were expressed as a percentage of leukocytes expressing them. Leukocyte glucocerebrosidase activity was measured by fluorometry. Results: The percentage of CD19+ leukocytes in Gaucher disease patients (8.2 +/- 3.4) was significantly higher than in the control group (4.8 +/- 3.4) (p < 0.05). The percentage of leukocytes expressing CD33 (12.8 +/- 6.6 vs 7.9 +/- 8.0, p=0.077), CD14 (10.6 +/- 4.6 vs 7.1 +/- 6.9, p=0.094) or CD8 (12.7 +/- 5.3 vs 9.8 +/- 5.9, p=0.115) was not significantly higher in patients than in controls. Discussion: The higher levels of CD19+ leukocytes may serve as a useful marker to predict leukocyte infiltration and perhaps also malignancy in Gaucher disease patients. Experimental anti-CD19 drugs are in development for the treatment of B cell cancers, and CD19+ leukocyte levels may also serve as a marker of the response to this treatment.en_US
dc.identifier.doi10.4328/JCAM.5418
dc.identifier.endpage60en_US
dc.identifier.issn1309-0720
dc.identifier.issn1309-2014
dc.identifier.issue1en_US
dc.identifier.startpage56en_US
dc.identifier.urihttps://doi.org/10.4328/JCAM.5418
dc.identifier.urihttps://hdl.handle.net/11454/31300
dc.identifier.volume9en_US
dc.identifier.wosWOS:000426502700014en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherDerman Medical Publen_US
dc.relation.ispartofJournal of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGaucher Diseaseen_US
dc.subjectLeucocyte Cell Surface Antigensen_US
dc.subjectCD19+en_US
dc.subjectMultiple Myelomaen_US
dc.subjectLeucocyte Infiltrationen_US
dc.subjectFlow Cytometryen_US
dc.titleHigher levels of CD19(+) leukocytes in Gaucher disease patients as a potential marker for malignancyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu